Riggs Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Riggs Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-650	Closed	-$13.5K	–	423
2023 Q3	$13.5K	Hold	650	–	–	﹤0.01%	221
2023 Q2	$15.6K	Hold	650	–	–	0.01%	207
2023 Q1	$12.2K	Hold	650	–	–	﹤0.01%	212
2022 Q4	$10.3K	Hold	650	–	–	﹤0.01%	208
2022 Q3	$11K	Hold	650	–	–	﹤0.01%	210
2022 Q2	$9K	Hold	650	–	–	﹤0.01%	206
2022 Q1	$16K	Hold	650	–	–	﹤0.01%	209
2021 Q4	$15K	Hold	650	–	–	﹤0.01%	223
2021 Q3	$11K	Hold	650	–	–	﹤0.01%	220
2021 Q2	$16K	Hold	650	–	–	﹤0.01%	214
2021 Q1	$17K	Hold	650	–	–	0.01%	193
2020 Q4	$35K	Sell	650 -16,820	-96%	-$835K	0.01%	144
2020 Q3	$2.02M	Buy	17,470 +16,820	+2,588%	+$726K	0.85%	35
2020 Q2	$31K	Hold	650	–	–	0.01%	118
2020 Q1	$27K	Hold	650	–	–	0.02%	121
2019 Q4	$28K	Hold	650	–	–	0.01%	159
2019 Q3	$23K	Hold	650	–	–	0.01%	153
2019 Q2	$17K	Hold	650	–	–	0.01%	160
2019 Q1	$17K	Hold	650	–	–	0.01%	158
2018 Q4	$11K	Hold	650	–	–	0.01%	154
2018 Q3	$13K	Hold	650	–	–	0.01%	162
2018 Q2	$10K	Hold	650	–	–	﹤0.01%	178
2018 Q1	$15K	Hold	650	–	–	0.01%	180
2017 Q4	$20K	Hold	650	–	–	0.01%	166
2017 Q3	$24K	Hold	650	–	–	0.01%	161
2017 Q2	$18K	Hold	650	–	–	0.01%	192
2017 Q1	$22K	Hold	650	–	–	0.01%	159
2016 Q4	$19K	Sell	650 -650	-50%	-$17.2K	0.01%	158
2016 Q3	$41K	Hold	1,300	–	–	0.02%	119
2016 Q2	$42K	Hold	1,300	–	–	0.02%	123
2016 Q1	$36K	Hold	1,300	–	–	0.03%	118
2015 Q4	$46K	Hold	1,300	–	–	0.02%	109
2015 Q3	$43K	Hold	1,300	–	–	0.03%	99
2015 Q2	$54K	Hold	1,300	–	–	0.03%	101
2015 Q1	$42K	Hold	1,300	–	–	0.02%	119
2014 Q4	$41K	Hold	1,300	–	–	0.02%	122
2014 Q3	$32K	Buy	+1,300	New	+$30.4K	0.02%	131

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Riggs Asset Management's ACAD Position: Q4 2023 in Review

Riggs Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2023, closing a stake of 650 shares — an estimated $13.5K sold.

Riggs Asset Management first reported a position in ACAD in Q3 2014 and held it in 37 quarters. The position peaked at $2.02M in Q3 2020. 276 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.

Riggs Asset Management reported no remaining Acadia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Riggs Asset Management sold 650 Acadia Pharmaceuticals shares in Q4 2023, an estimated $13.5K.
Riggs Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 37 quarters.
Riggs Asset Management's Acadia Pharmaceuticals position peaked at $2.02M in Q3 2020.
276 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.

Based on Riggs Asset Management's 13F filing for Q4 2023, filed 1 Feb 2024.